Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits.
|
30224653 |
2018 |
Alcoholic Intoxication, Chronic
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic Risk Variants Associated With Comorbid Alcohol Dependence and Major Depression.
|
29071344 |
2017 |
Alcohol-Related Disorders
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genetic Risk Variants Associated With Comorbid Alcohol Dependence and Major Depression.
|
29071344 |
2017 |
Alcohol-Induced Disorders
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genetic Risk Variants Associated With Comorbid Alcohol Dependence and Major Depression.
|
29071344 |
2017 |
Major Depressive Disorder
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic Risk Variants Associated With Comorbid Alcohol Dependence and Major Depression.
|
29071344 |
2017 |
Spinal Muscular Atrophy
|
0.050 |
Biomarker
|
disease |
BEFREE |
NCALD reduction is proven to be a protective modifier of SMA across species, including worm, zebrafish, and mice.
|
31230718 |
2019 |
Spinal Muscular Atrophy
|
0.050 |
Biomarker
|
disease |
BEFREE |
Taken together, our study identifies a novel link between NCALD and adult neurogenesis in the hippocampus, possibly <i>via</i> a MAP3K10-JNK pathway and emphasizes the safety of using NCALD reduction as a therapeutic option for SMA.
|
30853885 |
2019 |
Spinal Muscular Atrophy
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Both PLS3 overexpression and NCALD downregulation protect against SMA by restoring impaired endocytosis; however, the exact mechanism of this protection is largely unknown.
|
29961886 |
2018 |
Spinal Muscular Atrophy
|
0.050 |
Biomarker
|
disease |
BEFREE |
Expert commentary: The identification of genetic modifiers such as PLS3 and NCALD in humans or of SMA modulators such as Elavl4 (HuD), Copa, Uba1, Mapk10 (Jnk3), Nrxn2 and Tmem41b (Stasimon) in various SMA animal models improved our knowledge of impaired cellular pathways in SMA.
|
28635376 |
2017 |
Spinal Muscular Atrophy
|
0.050 |
Biomarker
|
disease |
BEFREE |
Importantly, NCALD knockdown effectively ameliorates SMA-associated pathological defects across species, including worm, zebrafish, and mouse.
|
28132687 |
2017 |
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The expression level of NCALD gene was associated with the prognosis of ovarian cancer and non-small cell lung cancer (NSCLC).
|
31109331 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Upregulation of long intergenic noncoding RNA 00673 promotes tumor proliferation via LSD1 interaction and repression of NCALD in non-small-cell lung cancer.
|
27027352 |
2016 |
Alzheimer's Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This observation could explain the changes of NCALD expression level in the brains of patients suffering from Alzheimer's disease because of the alteration of lipid composition in microdomains structures.
|
30469050 |
2019 |
Leukemia, Myelocytic, Acute
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We analyzed the NCALD gene expression with the prognosis and LSC of 165 AML patients from The Cancer Genome Atlas (TCGA) dataset and 78 AML patients from GEO dataset.
|
31109331 |
2019 |
ovarian neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression level of NCALD gene was associated with the prognosis of ovarian cancer and non-small cell lung cancer (NSCLC).
|
31109331 |
2019 |
Malignant neoplasm of ovary
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression level of NCALD gene was associated with the prognosis of ovarian cancer and non-small cell lung cancer (NSCLC).
|
31109331 |
2019 |
Cytogenetically normal acute myeloid leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
High NCALD-expressing CN-AML patients were associated with poor event-free survival (EFS) and overall survival (OS) compared to low NCALD expression (EFS, P < 0.0001, OS, P < 0.0001).
|
31109331 |
2019 |
Carcinoma, Ovarian Epithelial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The expression level of NCALD gene was associated with the prognosis of ovarian cancer and non-small cell lung cancer (NSCLC).
|
31109331 |
2019 |
Celiac Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
The differential expression of NTS and PPP1R12B indicate a potential role for smooth muscle contractility and cell proliferation in celiac disease, whereas other genes like GLS, NCALD and INSR suggests involvement of nutrient signaling and energy homeostasis in celiac disease pathogenesis.
|
26123480 |
2015 |
Diabetic Nephropathy
|
0.010 |
GeneticVariation
|
disease |
LHGDN |
These results suggest that the NCALD gene is a likely candidate for conferring susceptibility to diabetic nephropathy.
|
17671797 |
2007 |
Diabetic Nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that the NCALD gene is a likely candidate for conferring susceptibility to diabetic nephropathy.
|
17671797 |
2007 |